ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 95 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2021. The put-call ratio across all filers is 0.24 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,517 | -3.3% | 3,441 | +51.3% | 0.00% | 0.0% |
| Q2 2023 | $17,085 | +27456.5% | 2,275 | -83.4% | 0.00% | -50.0% |
| Q1 2023 | $62 | +376.9% | 13,694 | +1021.5% | 0.00% | +100.0% |
| Q4 2022 | $13 | -100.0% | 1,221 | -86.7% | 0.00% | 0.0% |
| Q3 2022 | $88,000 | +54.4% | 9,200 | +29.8% | 0.00% | 0.0% |
| Q2 2022 | $57,000 | +18.8% | 7,090 | +147.6% | 0.00% | – |
| Q1 2022 | $48,000 | -47.8% | 2,864 | -33.0% | 0.00% | -100.0% |
| Q4 2021 | $92,000 | -12.4% | 4,277 | +200.1% | 0.00% | -33.3% |
| Q3 2021 | $105,000 | +18.0% | 1,425 | -12.6% | 0.00% | +50.0% |
| Q2 2021 | $89,000 | +58.9% | 1,630 | +114.2% | 0.00% | +100.0% |
| Q1 2021 | $56,000 | -52.5% | 761 | -44.6% | 0.00% | -75.0% |
| Q4 2020 | $118,000 | +96.7% | 1,373 | -13.3% | 0.00% | +300.0% |
| Q3 2020 | $60,000 | – | 1,583 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $715,272,000 | 67.97% |
| Logos Global Management LP | 3,156,981 | $232,796,000 | 22.72% |
| Vivo Capital, LLC | 4,220,048 | $311,186,000 | 10.94% |
| Foresite Capital Management IV, LLC | 785,945 | $57,956,000 | 6.94% |
| Foresite Capital Management V, LLC | 320,000 | $23,597,000 | 6.94% |
| Board of Trustees of The Leland Stanford Junior University | 518,822 | $38,258,000 | 3.38% |
| Cormorant Asset Management, LP | 881,770 | $65,022,000 | 1.45% |
| Redmile Group, LLC | 978,600 | $72,162,000 | 1.02% |
| SPHERA FUNDS MANAGEMENT LTD. | 130,351 | $9,612,000 | 0.74% |
| Artal Group S.A. | 525,000 | $38,714,000 | 0.68% |